Pfizer stock dips on Q4 revenue miss, FY23 outlook sees COVID products decline

Jan. 31, 2023 7:45 AM ETPfizer Inc. (PFE), BNTXBy: Ravikash, SA News Editor47 Comments

Pfizer World Headquarters in New York City

Anne Czichos

Pfizer (NYSE:PFE) is trading lower premarket on Tuesday after mixed Q4 results and a full year 2023 outlook which is seen lower than expected.

Q4 Adjusted EPS grew +44% Y/Y to $1.14, beating estimates while revenue increased +2% to $24.29B but missed analysts expectations.

Recommended For You

Comments (47)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.